South Korea-based molecular diagnostics company Seegene has unveiled a global initiative for preemptive and routine COVID-19 PCR testing that the company hopes will cost just $12 per test.
The company's "in-life PCR" initiative includes asymptomatic testing for early virus detection and syndromic respiratory testing, as well as boosting PCR test accessibility through affordable pricing.
As part of the initiative, Seegene will provide the Allplex SARS-CoV-2 FluA/FluB/RSV assay, which can simultaneously detect SARS-CoV-2 via the N, RdRP, and S genes, influenza A and B, and respiratory syncytial virus (RSV) A/B.
In addition, Seegene will work with hospitals and labs so that a PCR test will cost approximately $12 to promote accessibility and encourage routine testing.
